Bleselumab

Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb) . Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM) . Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection[1].

Product Specifications

CAS Number

[1453067-91-8]

Product Name Alternative

ASKP 1240

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bleselumab.html

Purity

98.97

Solubility

10 mM in DMSO

Smiles

[Bleselumab]

Molecular Weight

(144.6 kDa)

References & Citations

[1]Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20 (1) :159-171. |[2]Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14 (6) :1290-9. |[3]Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98 (3) :267-76.